Phase I, Phase I
An Open-label, Multicenter, Phase I Study of IGM-8444 as a Single Agent and in Combination With Chemotherapy-based Regimens in Subjects With Relapsed and/or Refractory Solid Cancers
Volunteers
Health Professionals
What is the purpose of this trial?
This study is a first-in-human, Phase 1, multicenter, open-label study to determine the safety, tolerability and pharmacokinetics of IGM-8444 as a single agent and in combination with a chemotherapy-based regimen in patients with relapsed and/or refractory solid tumors.
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Armand Russo, MD
- Carrie Fijal, MSN, AGPCNP-BC, OCN
- Jacquelyne Gaddy, MD, MSc, MSCR
- Jane Kanowitz, MD
- Jeremy Kortmansky, MD
- Jill Lacy, MD
- Joseph Kim, MD
- Katelyn Scott
- Kirsten Dooley
- Kristen Hoxie
- Mandy DeMerchant
- Melissa Gambaccini
- Michael Cohenuram, MD
- Navid Hafez, MD, MPH
- Neal Fischbach, MD
- Pamela L. Kunz, MD
- Renee Moye
- Samantha Couillard
- Sara Anastasio, RN
- Stacey Stein, MD
- Teresa White
- Vanna Dest
- Virginia Syombathy
- Yifei Zhang, MD
- Last Updated04/18/2024
- Study HIC#2000028780